These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 1992624)
1. Cisapride: a new class of prokinetic agent. The ACG Committee on FDA-related matters. American College of Gastroenterology. McCallum RW Am J Gastroenterol; 1991 Feb; 86(2):135-49. PubMed ID: 1992624 [No Abstract] [Full Text] [Related]
2. Cisapride: its use in children. Newell SJ Br J Hosp Med; 1990 Dec; 44(6):408-9. PubMed ID: 2081312 [No Abstract] [Full Text] [Related]
3. [Prokinetic drugs]. Hellström P Nord Med; 1992; 107(11):274-7. PubMed ID: 1448341 [TBL] [Abstract][Full Text] [Related]
4. [Development of a new gastrointestinal prokinetic; pharmacology of cisapride]. Van Nueten JM; Schuurkes JA J Pharm Belg; 1991; 46(1):17-22. PubMed ID: 2051298 [TBL] [Abstract][Full Text] [Related]
6. Review of the current status of prokinetic agents in gastroenterology. McCallum RW Am J Gastroenterol; 1985 Dec; 80(12):1008-16. PubMed ID: 4072997 [No Abstract] [Full Text] [Related]
7. [Cisapride and other prokinetic agents in the treatment of gastroenterological diseases]. Ryss ES; Fishzon-Ryss IuI Ter Arkh; 1995; 67(2):58-61. PubMed ID: 7725263 [No Abstract] [Full Text] [Related]
11. The place of cisapride in therapeutics: an interim verdict. Hawkey CJ Aliment Pharmacol Ther; 1991 Aug; 5(4):351-6. PubMed ID: 1777545 [No Abstract] [Full Text] [Related]
12. Cisapride, a drug for long-term treatment? Harvengt C Acta Gastroenterol Belg; 1990; 53(4):369-71. PubMed ID: 2096582 [No Abstract] [Full Text] [Related]
13. Cisapride and 5-hydroxytryptamine enhance motility in the canine antrum via separate pathways, not involving 5-hydroxytryptamine1,2,3,4 receptors. de Ridder WJ; Schuurkes JA J Pharmacol Exp Ther; 1993 Jan; 264(1):79-88. PubMed ID: 8093733 [TBL] [Abstract][Full Text] [Related]
14. [[The effect of cisapride on the neurogenic bladder]. Hanson P; Soler JM Acta Belg Med Phys; 1989; 12(3):81-8. PubMed ID: 2603597 [TBL] [Abstract][Full Text] [Related]
15. Cisapride. Menezes O Aust Nurses J; 1991 Oct; 21(4):27. PubMed ID: 1750810 [No Abstract] [Full Text] [Related]
16. [Prokinetics in reflux disease. Action mechanisms and clinical effects]. Hatlebakk JG; Berstad A Tidsskr Nor Laegeforen; 1994 Feb; 114(6):689-92. PubMed ID: 8191452 [TBL] [Abstract][Full Text] [Related]
17. Use of prokinetic agents in special populations. Horn JR Am J Health Syst Pharm; 1996 Nov; 53(22 Suppl 3):S27-9. PubMed ID: 8931828 [TBL] [Abstract][Full Text] [Related]
18. Calcium-channel blockers and the gastrointestinal tract. American College of Gastroenterology's Committee on FDA related matters. Traube M; McCallum RW Am J Gastroenterol; 1984 Nov; 79(11):892-6. PubMed ID: 6391152 [No Abstract] [Full Text] [Related]
19. [A drive substance for the motor in digestion. Introduction]. Demling L Fortschr Med Suppl; 1990; 87():4. PubMed ID: 2351358 [No Abstract] [Full Text] [Related]
20. Cisapride in the treatment of chronic intestinal pseudo-obstruction. Reyntjens A; Verlinden M; Schuermans V Z Gastroenterol; 1990 Apr; 28 Suppl 1():79-84; discussion 92-3. PubMed ID: 2192509 [No Abstract] [Full Text] [Related] [Next] [New Search]